DOCSLIB.ORG

Appendix of Drugs *

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Appendix of Drugs * Appendix of Drugs * • Editor's Note: This appendix includes some of the most widely used trade names but should in no way be regarded as fully comprehensive. 374 Acepromazine maleate Acepromazine maleate but causes less potentiation of (Available as NotensilR , PlegizilR ) noradrenaline. Dosage is normally 25 mg Acepromazine is a phenothiazine derivative tds but this is often increased to SO mg tds. with anxiolytic and antipsychotic activity, The commonest side effects are drowsiness having its greatest use in psychotic patients and dry mouth. Other anti-cholinergic with excitement and aggressiveness. The effects are not uncommon. Amitriptyline dose is 10-25 mg tds for neuroses; should be used cautiously in patients with 50-100 mg tds for psychoses. Side cardiovascular disorders, and it is contra­ effects resemble those of chlorpromazine indicated in glaucoma, prostatic enlarge­ (g.v.) but occur less frequently and the ment and urinary retention. Care should contra-indications are as for chlorproma­ be taken when amitriptyline is given at the zine. same time as anti-hypertensive drugs. Except in special circumstances it should Acetylcarbromal not be combined with a monoamine (AbasinR ) oxidase inhibitor, and usually it is pre­ Acetylcarbromal is a mild sedative with ferable to wait at least three weeks after less hypnotic effect than carbromal (q.v.). discontinuing a monoamine oxidase I t produces sleep of short duration and is inhibitor before starting treatment with also used as an ambulatory sedative. The amitriptyline. normal dose is 250-500 mg tds. Few side effects occur at therapeutic doses but over Amphetamine sulphate longer periods symptoms resembling Amphetamine is a sympathomimetic chronic bromide poisoning may occur. amine with central nervous system stimu­ lant and anorectic activity. It is used to Acetophenazine maleate treat mild depressive neuroses and as an (TindaIR ) adjuvant in the treatment of chronic A phenothiazine derivative with action and alcoholism. The dose is 5 to 10 mg uses as chlorpromazine (q. v.) in anxiety morning and midday. Side effects include and schizophrenia. The daily dose ranges dryness of the mouth, restlessness, head­ from 40-80 mg. Its usefulness has not been ache, insomnia, irritability, dizziness, fully established. tremor and anorexia. Larger doses may give rise to fatigue, mental depression, an Amiphenazole hydrochloride increase in BP, fever, cardiovascular (DaptazoleR ) reactions, cyanosis and respiratory failure, Amiphenazole is an analeptic with an disorientation, hallucinations, convulsions, action similar to leptazol (q.v.) but less and coma. Continued use of amphetamine potent. I t is used in respiratory depression sulphate may cause addiction in some or failure and where large doses of mor­ patients. It is contra-indicated in cardio­ phine are necessary: Dosage is 15-20 mg vascular disease and thyrotoxicosis, and in with each dose of morphine, intramuscu­ those patients showing anxiety, hyper­ larly, and 100-200 mg tds or qds in excitability and restlessness. respiratory insufficiency. Side effects in­ The drug should be used with caution in clude nausea, vomiting, skin rashes and patients with anorexia, insomnia and insomnia. Amiphenazole may lead to bone nephritis. Caution should be taken if marrow depression following long term amphetamine is used concurrently with usage. monoamine oxidase inhibitors. Due to the liability of abuse the use of amphetamine Amitriptyline hydrochloride is no longer recommended. (LaroxyIR, LentizolR and SarotenR , TryptizolR; also a constituent of combina­ Amylobarbitone tions with various tranquillizers) (AmytaIR) Amitriptyline is a dibenzocycloheptadiene Amylobarbitone is an intermediate-acting derivative with potent anti-depressant barbiturate. It is used as a sedative and activity and mild anxiolytic properties. It hypnotic. The sedative dose is 15-50 is used in all forms of depression. It has mg bd or tds and 100-300 mg as a hypnotic. stronger anti-cholinergic and anti­ Its action, side effects and contra-indica­ histaminic ~.ctions than imipramine (q.v.), tions are as for barbiturates (q.v.) generally. Benzguinamide 375 Amylobarbitone sodium otherwise its properties are the same. (Sodium AmytalR ) Dose: 300 to 600 mg nocte. Being more speedily absorbed, amylo­ barbitone sodium provides a quicker Bemegride hypnotic action, otherwise its properties (MegimideR ) are the same as amylobarbitone (q.v.). An analeptic drug with a similar, but Hypnotic dose 100 to 200 mg nocte. longer, action to leptazol (q.v.) and nike­ I ts action, side effects and contra-indica­ thamide (g.v.), but less potent than tions are as for barbiturates (q.\".) generally. picrotoxin (q.y.). In use 10 ml of injection solution (50 mg of bemegride) are injected Anisoperidone every three to five minutes until the desired Anisoperidone is a butyrophenone result is obtained, or until a total dose of derivative used as a tranguillizer. It is less 1 g is reached. effective than haloperidol in schizophrenia, Toxic effects include retching, \·omiting, but greater anxiolytic activity than chlor­ muscular twitching and hypotension. promazine (q.v.) has been reported. Dose: 5 to 20 mg daily. Side effects include lack Benactyzine hydrochloride of drive, mild catatonia, nausea, vomiting (Formerly marketed as CafronR , and Parkinsonism. The place of this CevonoJlt, Lucidillt, NutinalR , SuavitilR , substance in clinical therapeutics has not and as an ingredient of Deprol R, Procalm R, yet been established. StoikonR) A diphenylmethane derivative with actions Apomorphine hydrochloride similar to meprobomate (g.v.). Used as a Apomorphine at a dose of 2-8 mg sub­ tranquillizer but now in disfavour owing to cutaneously is used as an emetic in the the number of side effects. Dosage 3-5 mg treatment of non-corrosive poisoning and tds. for aversion therapy in alcoholism. At 2 mg it has sedative and hypnotic effects. Benanserin Adverse reactions include hypotension, An indole derivative, benanserin has tachycardia and hypoventilation. It is psychotropic properties. The place of this contra-indicated in patients in shock or substance in clinical therapeutics has not deep narcosis. yet been established. Azocyclonol hydrochloride Benzoctarnine hydrochloride (Formerly available as Frenquel) (TacitinR) Azocyclonol is a neuroleptic found effective Benzoctamine is an anthracene derivative mainly in the treatment of acute schizo­ with anxiolytic and muscle relaxant phrenia. The dose of 20 to 100 mg tds properties. It is used in anxiety and tension produces few side effects, no sedation in dosages between 10 and 20 mg tds. Side results but skin rashes may occur. effects include lassitude, hypotension, impaired vision, sweating, gastrointestinal upsets and tachycardia. Barbitone (HypnogenR , formerly VeronalR ) Benzperidol Barbitone is one of the long-acting group (Synonym: benzperidol) of barbiturates, but is slow in producing (AnquiIR, FrenactylR, GlianimonR ) hypnosis. Although one of the least toxic A butyrophenone derivative reputed to be of the barbiturates, an intermediate or particularly effective in schizophrenia in short-acting barbiturate is preferred as a agitated geriatric patients and in the hypnotic. Normal dose is 300 to 600 mg. control of deviant and anti-social be­ As barbitone is excreted slowly its cumula­ haviour. The recommended daily dose is tion is a problem. 0·25-1·5 mg. Side effects are typical of the butyrophenones. Barbitone sodium (Previously available as MedinalR ) Benzquinamide Barbitone sodium produces hypnosis (QuantriIR; QuantrilR in the UK is a rather quicker than barbitone (g.v.), brand of caffeine citrate) 376 Bromazepam Benzquinamide is a weak tranquilii2;er used Butobarbitone in the treatment of anxiety and tension. (SoneryIR) The dose varies from 0·3 to 1 g daily and Butobarbitone is a member of the inter­ side effects include extrapyramidal effects, mediate acting barbiturates and used headache, vomiting, and dizziness. mainly as a hypnotic in insomnia, nervous or mental excitement and anxiety states. Bromazepam Dose: 100~200 mg. Side effects are those (LexomiIR , LexotanR , LexotaneR , Lexo­ normally associated with barbiturates (q.v .). tanillt) Bromazepam is a new member of the Butriptyline hydrochloride benzodiazepine group. It resembles (EvadyneR ) diazepam (q.v.) in clinical effects, par­ Butriptyline is a moderately sedative tri­ ticularly as an antianxiety agent at a cyclic antidepressant used in patients with daily dose of 4· 5~9 mg. Its side effects are depression associated with anxiety. The also similar to those of diazepam. daily dosage is between 75 and 150 mg/ day. Anticholinergic side effects are Bromocriptine present. A dopamine agonist which increases the production of prolactin inhibitory factor Butyrylperazine in the hypothalamus. A recent study sug­ SEE Butaperazine. gests that bromocriptine may have a part to play in the treatment of certain cases of Captodiame hydrochloride mania. (Formerly marketed in the United King­ dom as CovantinR, CovatixR) Bromvaletone (Marketed in USA as SuvrenR) (BromuraIH ) Captodiame hydrochloride has sedative Bromvaletone is chemically related to and anti-spasmodic properties and carbromal. It is a mild, rapidly acting has been used for the relief of tension, hypnotic with moderately short length of agitation and anxiety in minor neuroses action. It has low toxicity but the habitua­ and psychosomatic disorders. Dose: tion liability is similar to that of carbromal 50~100 mg tds. It is contra-indicated
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Thoroughbred Racing
    178CSR1 Title 178 Legislative Rule West Virginia Racing Commission Series 1 Thoroughbred Racing Effective: July 9, 2014 West Virginia Racing Commission 900 Pennsylvania Avenue Suite 533 Charleston WV 25302 305.558.2150 Fax 304.558.6319 Web Site: www.racing.wv.gov 178CSR1 Table of Contents SERIES 1 THOROUGHBRED RACING ____________________________________________________________________ 1 §178-1-1. General. ____________________________________________________________________________________ 1 PART 1. DEFINITIONS. _________________________________________________________________________________ 1 §178-1-2. Definitions. _________________________________________________________________________________ 1 PART 2. GENERAL AUTHORITY. ________________________________________________________________________ 9 §178-1-3. General Authority of the Racing Commission. ______________________________________________________ 9 §178-1-4. Power Of Entry. ______________________________________________________________________________ 9 §178-1-5. Racing Commission personnel. __________________________________________________________________ 9 §178-1-6. Ejection/Exclusion. __________________________________________________________________________ 12 PART 3. RACING OFFICIALS. __________________________________________________________________________ 12 §178-1-7. General Provisions. __________________________________________________________________________ 12 §178-1-8. Stewards. __________________________________________________________________________________ 14
    [Show full text]
  • BUREAU CIRCULAR No. 12 S. 1997
    REPUBLIC OF THE PHILIPPINES DEPARTMENT OF HEALTH BUREAU OF FOOD AND DRUGS D.O.H. Compound Alabang, Muntinlupa Metro Manila September 4, 1997 BUREAU CIRCULAR No. 12 series 1997 TO : ALL COSMETIC MANUFACTURERS, TRADERS, IMPORTERS AND PARTIES CONCERNED SUBJECT : 1997 UPDATED LISTING OF COSMETIC INGREDIENTS The BFAD Management Committee, in its meeting on August 28, 1997 has adopted and approved the updated technical standards and requirements set for cosmetic ingredients as recommended by the Joint BFAD and Cosmetic Industry Study Group’s Technical Committee. As such, the sections of Bureau Circular No. 19-A series of 1997 hereunder described are amended by the listings of cosmetic ingredients hereunto appended, to wit: Section III - Restricted Ingredients For Use In Cosmetics Table I : List Of Substances Which Cosmetics Products Must Not Contain Except Subject To The Restrictions And Conditions Specified Table II : List Of Preservatives Which Cosmetic Products May Contain Subject To The Restrictions And Conditions Specified Table III : List Of Preservatives Provisionally Allowed Section IV - Non-Permissible Colors In Cosmetics Table IV : Non-Permissible Colors In Cosmetics Section V - Permissible Color Additives Table V : Permissible Color Additives; List Of Colorants Restricted/Allowed For Cosmetic Products Table VI : List Of Provisionally Allowed Colors In Cosmetic Preparations Section VI: Sunscreen Agents Table VII : List Of Sunscreen Agents Which Cosmetics Products May Contain Table VIII : List Of Sunscreen Agents Which Cosmetics Products May Provisionally Contain Table IX : List Of Substances Which Must Not Form Part Of The Composition Of Cosmetic Products Additionally, BFAD has decided to extend the approval of products containing benzethonium chloride only up to December 31, 1997 in view of the ban of the said ingredient under the European Economic Community’s (EEC) August 1996 Directive, unless additional safety data on the same are found before December 31, 1997.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Treatment of Schizophrenia Course Director: Philip Janicak, M.D
    S6735- Treatment of Schizophrenia Course Director: Philip Janicak, M.D. #APAAM2016 Saturday, May 14, 2016 Marriott Marquis - Marquis Ballroom D psychiatry.org/ annualmeetingS4637 ANNUAL MEETING May 14-18, 2016 • Atlanta Reference • Janicak PG, Marder SR, Tandon R, Goldman M (Eds.). Schizophrenia: Recent Advances in Diagnosis and Treatment. New York, NY: Springer; 2014. Schizophrenia: Recent Diagnostic Advances, Neurobiology, and the Neuropharmacology of Antipsychotic Drug Therapy Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine Gainesville, Florida Annual Meeting of the American Psychiatric Association New York, New York May 3–7, 2014 Disclosure Information MEMBER, WPA PHARMACOPSYCHIATRY SECTION MEMBER, DSM-5 WORKGROUP ON PSYCHOTIC DISORDERS A CLINICIAN AND CLINICAL RESEARCHER Pharmacological Treatment of Any Disease • Know the Disease that you are treating • Nature; Treatment targets; Treatment goals; • Know the Treatments at your disposal • What they do; How they compare; Costs; • Principles of Treatment • Measurement-based; Targeted; Individualized Program Outline • Nature and Definition of psychosis? • Clinical description • What is wrong in psychotic illness • Dimensions of Psychopathology • Neurobiological Abnormalities • Mechanisms underlying antipsychotic effects? • What contributes to Efficacy • Basis of Side-effect differences 5 Challenges in DSM-IV Construct of Psychotic Disorders ♦ Indistinct Boundaries ♦ With Other Disorders (eg., with OCD) ♦ Within Group of Psychotic Disorders (eg. between
    [Show full text]
  • Psychiatric Medications in Behavioral Healthcarev5
    Copyright © The University of South Florida, 2012 Psychiatric Medications in Behavioral Healthcare An Important Notice None of the pages in this tutorial are meant to be a replacement for professional help. The science of medicine is constantly changing, and these changes alter treatment and drug therapies as a result of what is learned through research and clinical experience. The author has relied on resources believed to be reliable at the time material was developed. However, there is always the possibility of human error or changes in medical science and neither the authors nor the University of South Florida can guarantee that all the information in this program is in every respect accurate or complete and they are not responsible for any errors or omissions or for the results obtained from the use of such information. Each person that reads this program is encouraged to confirm the information with other sources and understand that it not be interpreted as medical or professional advice. All medical information needs to be carefully reviewed with a health care provider. Course Objectives At the completion of this program participants should be able to: • Identify at 5 categories of medications used to treat the symptoms of psychiatric disorders, the therapeutic effects of medications in each category, and the side effects associated with medications in each category. • Identify at least 5 medications and the benefits of those medications as compared to the medications. • Identify at least 5 reasons that a person may stop taking medications or not take medications as prescribed. • Demonstrate your learned understanding of psychiatric medications by passing the combined post‐ tests.
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]